<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="description" content="Why do migraine attacks cluster around your period? The estrogen drop, the prostaglandin surge, and what clinical trials actually prove works. Evidence from 28 peer-reviewed studies.">
    <meta name="author" content="Rustam Iuldashov">
    <meta name="keywords" content="menstrual migraine, hormonal migraine, estrogen withdrawal, period migraine, CGRP migraine treatment, frovatriptan, migraine prevention, menstrual cycle migraine triggers">
    <title>The Body Keeps the Calendar: Menstrual Migraines Explained | Migraine Companion</title>
    <link rel="icon" type="image/png" href="images/mi-icon.png">
    <link rel="canonical" href="https://migrainecompanion.app/the-body-keeps-the-calendar.html">
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700;800&family=Cormorant+Garamond:ital,wght@0,400;0,500;0,600;1,400;1,500&display=swap" rel="stylesheet">

    <!-- Schema.org markup for EEAT -->
    <script type="application/ld+json">
    {
        "@context": "https://schema.org",
        "@type": "Article",
        "headline": "The Body Keeps the Calendar: Menstrual Migraines Explained",
        "description": "Inside the biology of menstrual migraine ‚Äî and the evidence-based strategies that can finally disrupt the cycle. Based on 28 peer-reviewed sources including NEJM, Neurology, and Cephalalgia.",
        "image": "https://migrainecompanion.app/images/article-body-calendar.png",
        "author": {
            "@type": "Person",
            "name": "Rustam Iuldashov",
            "description": "Developer of Migraine Companion with 30+ years of personal migraine experience",
            "url": "https://migrainecompanion.app/about"
        },
        "publisher": {
            "@type": "Organization",
            "name": "Migraine Companion",
            "logo": {
                "@type": "ImageObject",
                "url": "https://migrainecompanion.app/images/mi-icon.png"
            }
        },
        "datePublished": "2026-02-04",
        "dateModified": "2026-02-04",
        "mainEntityOfPage": {
            "@type": "WebPage",
            "@id": "https://migrainecompanion.app/the-body-keeps-the-calendar.html"
        },
        "about": {
            "@type": "MedicalCondition",
            "name": "Menstrual Migraine"
        },
        "speakable": {
            "@type": "SpeakableSpecification",
            "cssSelector": [".article-subtitle", ".key-takeaways"]
        }
    }
    </script>

    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        :root {
            --lavender: #8b7aa8;
            --gold: #C5A059;
            --antique-gold: #D5B069;
            --bg: #0d0d0d;
            --text: #d0d0d0;
            --text-light: #a0a0a0;
            --text-dark: #888;
        }

        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
            -webkit-font-smoothing: antialiased;
        }

        .container {
            max-width: 780px;
            margin: 0 auto;
            padding: 0 24px;
        }

        header {
            padding: 16px 0;
            position: fixed;
            width: 100%;
            top: 0;
            z-index: 100;
            background: rgba(13, 13, 13, 0.95);
            backdrop-filter: blur(10px);
            border-bottom: 1px solid rgba(139, 122, 168, 0.15);
        }

        .header-content {
            max-width: 1100px;
            margin: 0 auto;
            padding: 0 24px;
            display: flex;
            justify-content: space-between;
            align-items: center;
        }

        .logo {
            font-size: 1.3rem;
            font-weight: 700;
            color: #ffffff;
            letter-spacing: -0.3px;
            text-decoration: none;
        }

        .logo span {
            color: var(--lavender);
        }

        .back-link {
            color: var(--text-light);
            text-decoration: none;
            font-size: 0.9rem;
            font-weight: 500;
            transition: color 0.3s;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .back-link:hover {
            color: var(--lavender);
        }

        .article-hero {
            margin-top: 70px;
            position: relative;
            overflow: hidden;
            border-radius: 0 0 24px 24px;
            height: 600px;
            display: flex;
            align-items: center;
            justify-content: center;
        }

        .article-hero img {
            position: absolute;
            top: 0;
            left: 0;
            width: 100%;
            height: 100%;
            object-fit: cover;
            z-index: 0;
        }

        .article-hero::after {
            content: '';
            position: absolute;
            top: 0;
            left: 0;
            right: 0;
            bottom: 0;
            background: linear-gradient(to bottom, rgba(13,13,13,0.4) 0%, rgba(13,13,13,0.8) 100%);
            z-index: 1;
        }

        .article-header {
            position: relative;
            z-index: 2;
            text-align: center;
            padding: 0 24px;
        }

        .article-tag {
            display: inline-block;
            background: rgba(197, 160, 89, 0.2);
            border: 1px solid rgba(197, 160, 89, 0.4);
            color: var(--gold);
            font-size: 0.75rem;
            font-weight: 600;
            padding: 6px 14px;
            border-radius: 20px;
            margin-bottom: 20px;
            letter-spacing: 0.5px;
            text-transform: uppercase;
        }

        h1 {
            font-family: 'Cormorant Garamond', serif;
            font-size: 2.8rem;
            font-weight: 600;
            line-height: 1.2;
            color: #ffffff;
            margin-bottom: 16px;
            letter-spacing: -0.02em;
            text-shadow: 0 2px 20px rgba(0,0,0,0.8);
        }

        .article-subtitle {
            font-size: 1.15rem;
            font-weight: 500;
            color: rgba(255,255,255,0.85);
            font-style: italic;
            text-shadow: 0 2px 10px rgba(0,0,0,0.7);
        }

        .article-meta {
            display: flex;
            align-items: center;
            justify-content: center;
            gap: 20px;
            margin-top: 20px;
            font-size: 0.85rem;
            color: rgba(255,255,255,0.7);
        }

        .article-content {
            padding: 60px 0 80px;
        }

        .article-section {
            margin-bottom: 48px;
        }

        h2 {
            font-family: 'Cormorant Garamond', serif;
            font-size: 1.9rem;
            font-weight: 600;
            color: #ffffff;
            margin-bottom: 20px;
            letter-spacing: -0.01em;
            line-height: 1.3;
        }

        p {
            font-size: 1.05rem;
            line-height: 1.8;
            margin-bottom: 20px;
            color: var(--text);
        }

        strong {
            font-weight: 700;
            color: var(--antique-gold);
        }

        em {
            font-style: italic;
            color: var(--text-light);
        }

        .article-image {
            margin: 48px 0;
            border-radius: 16px;
            overflow: hidden;
            box-shadow: 0 20px 60px rgba(0,0,0,0.4);
        }

        .article-image img {
            width: 100%;
            height: auto;
            display: block;
        }

        .article-image figcaption {
            background: rgba(139, 122, 168, 0.1);
            padding: 12px 16px;
            font-size: 0.85rem;
            color: var(--text-light);
            text-align: center;
            font-style: italic;
        }

        .highlight-box {
            background: rgba(197, 160, 89, 0.08);
            border-left: 3px solid var(--gold);
            padding: 24px 28px;
            border-radius: 0 12px 12px 0;
            margin: 36px 0;
        }

        .highlight-box p {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--antique-gold);
            margin: 0;
            line-height: 1.7;
        }

        .quote-box {
            background: rgba(139, 122, 168, 0.08);
            border-left: 3px solid var(--lavender);
            padding: 24px 28px;
            border-radius: 0 12px 12px 0;
            margin: 36px 0;
        }

        .quote-box p {
            font-family: 'Cormorant Garamond', serif;
            font-size: 1.25rem;
            font-style: italic;
            color: #ffffff;
            margin: 0;
            line-height: 1.7;
        }

        .separator {
            text-align: center;
            margin: 60px 0;
            color: var(--lavender);
            font-size: 1.5rem;
            opacity: 0.5;
        }

        .article-footer {
            margin-top: 60px;
            padding-top: 40px;
            border-top: 1px solid rgba(139, 122, 168, 0.15);
        }

        .author-card {
            display: flex;
            align-items: center;
            gap: 20px;
            background: rgba(255, 255, 255, 0.03);
            border: 1px solid rgba(139, 122, 168, 0.12);
            border-radius: 16px;
            padding: 24px;
            margin-bottom: 32px;
        }

        .author-avatar {
            width: 80px;
            height: 80px;
            border-radius: 50%;
            background: linear-gradient(135deg, var(--lavender), var(--gold));
            padding: 3px;
            flex-shrink: 0;
        }

        .author-avatar img {
            width: 100%;
            height: 100%;
            border-radius: 50%;
            object-fit: cover;
        }

        .author-info h3 {
            font-size: 1.1rem;
            font-weight: 700;
            color: #ffffff;
            margin-bottom: 4px;
        }

        .author-info p {
            font-size: 0.9rem;
            color: var(--text-light);
            margin: 0;
            line-height: 1.5;
        }

        .cta-box {
            background: rgba(197, 160, 89, 0.08);
            border: 1px solid rgba(197, 160, 89, 0.2);
            border-radius: 16px;
            padding: 32px;
            text-align: center;
        }

        .cta-box h3 {
            font-size: 1.3rem;
            font-weight: 700;
            color: #ffffff;
            margin-bottom: 12px;
        }

        .cta-box p {
            font-size: 1rem;
            color: var(--text-light);
            margin-bottom: 24px;
        }

        .download-btn {
            display: inline-flex;
            align-items: center;
            gap: 12px;
            padding: 14px 28px;
            background: linear-gradient(135deg, rgba(197,160,89,0.2), rgba(197,160,89,0.3));
            border: 1px solid var(--gold);
            border-radius: 12px;
            color: var(--gold);
            text-decoration: none;
            font-weight: 600;
            transition: all 0.3s;
        }

        .download-btn:hover {
            background: var(--gold);
            color: var(--bg);
            transform: translateY(-2px);
        }

        .references {
            margin-top: 48px;
            padding-top: 32px;
            border-top: 1px solid rgba(139, 122, 168, 0.1);
        }

        .references h3 {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text-light);
            margin-bottom: 16px;
        }

        .references ol {
            padding-left: 20px;
        }

        .references li {
            font-size: 0.85rem;
            color: var(--text-dark);
            margin-bottom: 8px;
            line-height: 1.5;
        }

        .references a {
            color: var(--lavender);
            text-decoration: none;
        }

        .references a:hover {
            text-decoration: underline;
        }

        sup {
            color: var(--lavender);
            font-weight: 600;
        }

        footer {
            padding: 40px 0;
            border-top: 1px solid rgba(139, 122, 168, 0.12);
            text-align: center;
        }

        .copyright {
            color: var(--text-dark);
            font-size: 0.85rem;
        }

        .medical-disclaimer {
            font-size: 0.9rem;
            font-style: italic;
            color: var(--text-dark);
            text-align: center;
            padding: 16px 0;
            margin-bottom: 48px;
            border-bottom: 1px solid rgba(139, 122, 168, 0.1);
        }

        .key-takeaways {
            background: rgba(139, 122, 168, 0.08);
            border: 1px solid rgba(139, 122, 168, 0.2);
            border-radius: 16px;
            padding: 28px;
            margin: 48px 0;
        }

        .key-takeaways h3 {
            font-size: 1.1rem;
            font-weight: 700;
            color: #ffffff;
            margin-bottom: 16px;
        }

        .key-takeaways ul {
            list-style: none;
            padding: 0;
            margin: 0;
        }

        .key-takeaways li {
            font-size: 0.95rem;
            color: var(--text);
            padding: 8px 0;
            padding-left: 24px;
            position: relative;
        }

        .key-takeaways li::before {
            content: '‚Üí';
            position: absolute;
            left: 0;
            color: var(--lavender);
        }

        .editorial-standards {
            background: rgba(139, 122, 168, 0.05);
            border: 1px solid rgba(139, 122, 168, 0.15);
            border-radius: 16px;
            padding: 28px;
            margin: 32px 0;
        }

        .editorial-standards h3 {
            font-size: 1.1rem;
            font-weight: 700;
            color: #ffffff;
            margin-bottom: 16px;
        }

        .editorial-standards ul {
            list-style: none;
            padding: 0;
            margin: 0;
        }

        .editorial-standards li {
            font-size: 0.9rem;
            color: var(--text-light);
            padding: 6px 0;
            padding-left: 20px;
            position: relative;
        }

        .editorial-standards li::before {
            content: '‚Ä¢';
            position: absolute;
            left: 0;
            color: var(--lavender);
        }

        .when-to-see-doctor {
            background: rgba(197, 160, 89, 0.05);
            border: 1px solid rgba(197, 160, 89, 0.2);
            border-radius: 16px;
            padding: 28px;
            margin: 32px 0;
        }

        .when-to-see-doctor h3 {
            font-size: 1.1rem;
            font-weight: 700;
            color: var(--gold);
            margin-bottom: 16px;
        }

        .when-to-see-doctor ul {
            list-style: none;
            padding: 0;
            margin: 0 0 16px 0;
        }

        .when-to-see-doctor li {
            font-size: 0.9rem;
            color: var(--text);
            padding: 6px 0;
            padding-left: 20px;
            position: relative;
        }

        .when-to-see-doctor li::before {
            content: '‚ö†';
            position: absolute;
            left: 0;
            font-size: 0.8rem;
        }

        .when-to-see-doctor p {
            font-size: 0.9rem;
            color: var(--text-light);
            margin: 0;
            font-style: italic;
        }

        .review-dates {
            text-align: center;
            font-size: 0.8rem;
            color: var(--text-dark);
            margin-top: 32px;
            padding-top: 16px;
            border-top: 1px solid rgba(139, 122, 168, 0.1);
        }

        @media (max-width: 768px) {
            h1 { font-size: 2rem; }
            h2 { font-size: 1.5rem; }
            .article-hero { height: 400px; }
            p { font-size: 1rem; }
            .article-content { padding: 40px 0 60px; }
            .author-card { flex-direction: column; text-align: center; }
            .article-meta { flex-direction: column; gap: 8px; }
        }
    </style>
</head>
<body>
    <header>
        <div class="header-content">
            <a href="index.html" class="logo">M<span>I</span>graine Companion</a>
            <a href="blog.html" class="back-link">‚Üê Back to Blog</a>
        </div>
    </header>

    <main>
        <div class="article-hero">
            <img src="images/article-body-calendar.png" alt="Cinematic visualization of estrogen withdrawal cliff ‚Äî a luminous crystalline drop symbolizing the hormonal trigger of menstrual migraine">
            <div class="article-header">
                <span class="article-tag">Science</span>
                <h1>The Body Keeps the Calendar</h1>
                <p class="article-subtitle">Inside the biology of menstrual migraine ‚Äî and the evidence-based strategies that can finally disrupt the cycle.</p>
                <div class="article-meta">
                    <span>üìÖ February 8, 2026</span>
                    <span>‚è± 8 min read</span>
                    <span>‚úçÔ∏è Rustam Iuldashov</span>
                </div>
            </div>
        </div>

        <article class="article-content">
            <div class="container">

                <!-- AUTHOR BYLINE -->
                <div style="text-align:center;padding:32px 0 16px;">
                    <p style="font-size:1rem;font-weight:600;color:#ffffff;margin-bottom:8px;">
                        By Rustam Iuldashov
                    </p>
                    <p style="font-size:0.9rem;font-weight:500;color:var(--text-light);margin:0;">
                        30 years lived experience with chronic migraine | Last updated: February 8, 2026
                    </p>
                </div>

                <!-- MEDICAL DISCLAIMER -->
                <p class="medical-disclaimer">
                    <strong>Medical Review:</strong> This content is based on 28 peer-reviewed sources including the <em>New England Journal of Medicine</em>, <em>Neurology</em>, <em>Cephalalgia</em>, <em>The Journal of Headache and Pain</em>, and the SWAN longitudinal cohort study.<br><br>
                    <strong>Important Notice:</strong> This article is for informational purposes only and does not replace professional medical advice. Always consult a healthcare professional before starting or changing any treatment.
                </p>

                <!-- OPENING -->
                <section class="article-section">
                    <p>Two days before her period, Sarah cancels dinner. She already knows. Not from the cramp ‚Äî that comes later ‚Äî but from the shadow behind her right eye, the slow thickening of light into something hostile. By morning, she will be in bed with the curtains drawn, a washcloth on her forehead, hours lost.</p>
                    <p>She has lived this rhythm for fourteen years.</p>
                    <p>Sarah is not unusual. Nearly 50% of women with migraine report a connection between their attacks and their menstrual cycle.<sup>[1]</sup> Among them, a significant proportion experience what neurologists classify as menstrual migraine ‚Äî attacks striking within a precise five-day window, from two days before menstruation to three days into bleeding, in at least two out of three consecutive cycles.<sup>[2]</sup> These are not ordinary migraines that happen to coincide with a period. They last longer. They hit harder. They resist the medications that work at other times of the month. And they are more likely to return after initial relief.<sup>[3]</sup></p>
                    <p>Yet no drug on Earth carries an FDA-approved indication specifically for menstrual migraine.<sup>[4]</sup></p>
                    <p>How is that possible?</p>
                </section>

                <!-- IMAGE 1: THE CLIFF -->
                <figure class="article-image">
                    <img src="images/hormone_cliff_estrogen_drop.png" alt="The Hormone Cliff ‚Äî cinematic visualization of the dramatic estrogen withdrawal that triggers menstrual migraine">
                    <figcaption>The Hormone Cliff ‚Äî Estrogen doesn't just decline before menstruation. In migraineurs, it plummets 46% faster than in controls (SWAN, n = 3,302)</figcaption>
                </figure>

                <div class="separator">* * *</div>

                <!-- THE CLIFF -->
                <section class="article-section">
                    <h2>The Cliff</h2>
                    <p>The answer begins with a discovery made in 1972 by an Australian neurologist named Brian Somerville. His experiment was deceptively simple: inject estradiol into women who reliably developed migraines before their periods, then observe.<sup>[5]</sup></p>
                    <p>The migraines vanished ‚Äî temporarily. They reappeared days later, precisely when the injected estrogen wore off and levels plummeted. The attacks didn't follow the period. They followed the fall.</p>
                    <p>Somerville's work established what scientists now call the estrogen withdrawal hypothesis, and more than fifty years of subsequent research has confirmed its central claim.<sup>[6]</sup> The trigger is not low estrogen itself. It is the speed of the decline. The steeper the drop, the harder the crash.</p>
                    <p>In 2016, a landmark study within the SWAN cohort ‚Äî a multiethnic, prospective study tracking 3,302 women through midlife ‚Äî measured this directly.<sup>[7]</sup> Researchers collected daily urinary hormone samples and matched them against headache diaries. The finding was striking: women with migraine showed a 46% greater rate of estrogen decline in the two days after their luteal peak compared with controls (p = 0.002).<sup>[7]</sup> The migraine brain doesn't merely experience the hormonal drop. It falls faster and farther.</p>
                    <p>Dr. Anne MacGregor, whose research led to the International Headache Society's diagnostic criteria for menstrual migraine, demonstrated the same pattern across three consecutive menstrual cycles using daily urinary assays.<sup>[8]</sup> Migraine incidence climbed specifically during the phase of falling estrogen. Rising estrogen appeared protective. The women who blamed their hormones were right.</p>
                </section>

                <div class="separator">* * *</div>

                <!-- THE CASCADE -->
                <section class="article-section">
                    <h2>The Cascade</h2>
                    <p>If estrogen withdrawal were the whole story, the solution would be simple: stabilize hormones, stop migraines. But biology rarely cooperates. When estrogen drops, it triggers not one disruption but three ‚Äî each amplifying the others.</p>
                    <p><strong>Serotonin crashes.</strong> Estrogen directly regulates serotonin synthesis. When estrogen declines, serotonin production slows. Simultaneously, the enzyme that destroys serotonin ‚Äî monoamine oxidase ‚Äî accelerates.<sup>[9]</sup> Less being made; more being destroyed. This dual collapse may explain why triptans, which depend on serotonin receptors, often underperform against menstrual attacks: the very receptors they target become desensitized when estrogen runs low.<sup>[10]</sup></p>
                    <p><strong>The brain's painkillers go offline.</strong> During the late luteal phase, the capacity to activate Œº-opioid receptors ‚Äî the same system targeted by morphine ‚Äî becomes impaired.<sup>[11]</sup> Pain signals that would normally be dampened arrive at full volume.</p>
                    <p><strong>Prostaglandins flood the system.</strong> Here menstrual migraine diverges most sharply from ordinary migraine. During the first 48 hours of menstruation, the uterus releases prostaglandin E2 ‚Äî and these molecules don't stay local. Prostaglandin levels can triple between the follicular and menstrual phases.<sup>[10]</sup> PGE2 provokes the release of calcitonin gene-related peptide (CGRP) from trigeminal nerve fibers, dilating blood vessels and igniting neurogenic inflammation in the meninges.<sup>[12]</sup> Animal models confirm that PGE2 concentrations in pain-processing brain regions rise specifically during periods of low sex hormones, directly increasing CGRP expression.<sup>[12]</sup></p>
                    <p>MacGregor identified these as two completely independent triggers.<sup>[13]</sup> A woman may be vulnerable to the hormonal drop, to the prostaglandin surge, or to both. This explains a clinical puzzle: why some treatments work for some women and fail for others. The triggers differ. So must the strategy.</p>
                </section>

                <!-- IMAGE 2: TRIPLE CASCADE -->
                <figure class="article-image">
                    <img src="images/triple_cascade_serotonin_prostaglandin_cgrp.png" alt="The Triple Cascade ‚Äî cinematic visualization of three simultaneous neurochemical disruptions triggered by estrogen withdrawal">
                    <figcaption>The Triple Cascade ‚Äî Three systems collapse simultaneously: serotonin crashes, opioid receptors shut down, prostaglandins surge ‚Äî converging on CGRP activation</figcaption>
                </figure>

                <div class="separator">* * *</div>

                <!-- THE NATURAL EXPERIMENTS -->
                <section class="article-section">
                    <h2>The Natural Experiments</h2>
                    <p>Science often depends on controlled conditions. Nature, occasionally, provides them for free.</p>
                    <p><strong>Pregnancy.</strong> During the second and third trimesters, estrogen rises steadily ‚Äî no cliffs, no crashes. About 50% of women with migraine improve by the end of the first trimester. By the second, that figure reaches 80%.<sup>[14]</sup> Women with menstrual migraine without aura benefit the most. This isn't correlation. It's a direct test of the estrogen-stability hypothesis.</p>
                    <p><strong>Perimenopause.</strong> The opposite experiment. As ovarian function becomes erratic, estrogen spikes and crashes more dramatically than during any normal cycle. The SWAN study found that women with migraine history experienced significantly higher frequency of headache during the late perimenopausal period (31%) compared with premenopausal controls (16.7%) in a cross-sectional analysis of 1,436 women.<sup>[15]</sup> The American Migraine Prevalence and Prevention Study (n = 3,664 women with migraine) confirmed the association: perimenopause and menopause significantly increased the risk of high-frequency headache, defined as more than ten days per month.<sup>[16]</sup></p>
                    <p><strong>Menopause.</strong> Once estrogen finally stabilizes ‚Äî even at persistently low levels ‚Äî approximately two-thirds of women with spontaneous menopause see significant improvement.<sup>[17]</sup> But women who undergo surgical menopause, with its abrupt hormonal plunge, see migraines worsen in two-thirds of cases.<sup>[17]</sup></p>

                    <div class="highlight-box">
                        <p>The pattern is unmistakable across all four life stages. It's the volatility, not the volume.</p>
                    </div>
                </section>

                <!-- IMAGE 3: LIFECYCLE -->
                <figure class="article-image">
                    <img src="images/lifecycle_pregnancy_perimenopause_menopause.png" alt="A woman's migraine journey across four life stages ‚Äî from reproductive years through pregnancy, perimenopause, and menopause">
                    <figcaption>The Lifecycle ‚Äî Four natural experiments prove the same principle: stable estrogen protects, volatile estrogen attacks</figcaption>
                </figure>

                <div class="separator">* * *</div>

                <!-- THE EVIDENCE -->
                <section class="article-section">
                    <h2>The Evidence</h2>
                    <p>Understanding the mechanism is necessary. It is not sufficient. What follows is what the clinical trial data actually support ‚Äî organized from simplest intervention to most targeted, with sample sizes and effect sizes included.</p>

                    <p><strong>Three months of tracking comes first.</strong> The International Headache Society requires documentation across at least two of three consecutive cycles for diagnosis.<sup>[2]</sup> Research confirms that self-reported menstrual migraine is frequently overdiagnosed without prospective diaries.<sup>[3]</sup> A dual diary ‚Äî migraine days alongside menstrual days ‚Äî remains the diagnostic foundation.</p>

                    <p><strong>Timed NSAIDs.</strong> A double-blind, placebo-controlled trial by Sances and colleagues (n = 34) demonstrated that naproxen sodium (550 mg twice daily), started two days before expected menstruation and continued through day three of bleeding, significantly reduced headache frequency, severity, and duration compared with placebo.<sup>[18]</sup> The mechanism is direct: naproxen inhibits cyclooxygenase, blocking the prostaglandin surge that triggers CGRP release.<sup>[4]</sup> For women whose migraines travel with painful or heavy periods ‚Äî a sign of elevated prostaglandin production ‚Äî this approach does double duty.</p>

                    <p><strong>Magnesium from cycle day 15.</strong> A double-blind, placebo-controlled trial by Facchinetti and colleagues (n = 20) found that 360 mg of oral magnesium daily, begun on day 15 of the cycle and continued until the next period, significantly reduced both menstrual migraine attacks and premenstrual symptoms.<sup>[19]</sup> Critically, intracellular magnesium levels were measurably lower in migraine patients at baseline and rose significantly with supplementation, suggesting a direct physiological correction rather than a placebo effect.<sup>[19]</sup> Magnesium glycinate is gentler on the stomach; magnesium citrate works better if constipation is a concern.</p>

                    <p><strong>Vitamin E mini-course.</strong> A randomized, double-blind, placebo-controlled trial found that 400 IU of vitamin E daily for five days ‚Äî starting two days before menstruation and continuing three days after ‚Äî significantly reduced pain intensity, functional disability, and associated symptoms including photophobia and phonophobia.<sup>[20]</sup></p>

                    <p><strong>Frovatriptan mini-prevention.</strong> The largest and most rigorous trial data exist for this approach. Silberstein and colleagues randomized 546 women in a double-blind, placebo-controlled, three-way crossover design.<sup>[21]</sup> Each participant treated three perimenstrual periods with placebo, frovatriptan 2.5 mg once daily, or frovatriptan 2.5 mg twice daily, starting two days before anticipated migraine and continuing for six days. The results: menstrual migraine occurred during 67% of placebo periods, 52% of once-daily periods, and 41% of twice-daily periods (p &lt; 0.0001 for both doses versus placebo). Both regimens also significantly reduced migraine severity, duration, and rescue medication use.<sup>[21]</sup> A second trial specifically targeting women with treatment-resistant menstrual migraine (n = 410) confirmed these findings, with the twice-daily regimen doubling the number of headache-free perimenstrual periods compared with placebo (p &lt; 0.001).<sup>[22]</sup> A meta-analysis of six randomized controlled trials totaling over 2,800 participants established frovatriptan 2.5 mg twice daily as the most effective triptan for menstrual migraine prevention (RR 1.98, 95% CI 1.68‚Äì2.34 versus placebo).<sup>[23]</sup></p>

                    <p><strong>Hormonal stabilization.</strong> Estrogen supplementation ‚Äî via transdermal patch, gel, or continuous low-dose oral contraceptives without placebo breaks ‚Äî attacks the root mechanism by preventing the estrogen cliff.<sup>[24]</sup> MacGregor's research demonstrated that eliminating or shortening the hormone-free interval can substantially reduce menstrual attacks.<sup>[8]</sup> This path requires careful individualized assessment, particularly for women with migraine with aura, in whom estrogen-containing contraceptives carry elevated cardiovascular risk.<sup>[4]</sup></p>

                    <p><strong>CGRP-targeting therapies.</strong> These represent the most significant advance in migraine treatment in decades ‚Äî and recent evidence confirms their relevance to menstrual migraine specifically. The STRIVE trial (n = 955), published in the <em>New England Journal of Medicine</em>, demonstrated that erenumab ‚Äî a monoclonal antibody targeting the CGRP receptor ‚Äî reduced monthly migraine days by approximately 3.7 days at the 140 mg dose, with 50% of patients achieving at least a 50% reduction in migraine frequency versus 26.6% on placebo.<sup>[25]</sup> A 2024 meta-analysis of 26 randomized controlled trials confirmed that both erenumab and galcanezumab significantly outperformed triptans in reducing monthly headache days when used as preventive therapy for menstrual migraine, with mean reductions of 2.1 and 2.4 days respectively.<sup>[26]</sup> Real-world data from Italian headache centers showed that CGRP monoclonal antibodies reduced menstrual migraine days from five to two per cycle, cut mean attack duration from 24 to 8 hours, and improved acute medication response rates from 42.5% to 95%.<sup>[27]</sup></p>
                </section>

                <!-- IMAGE 4: EVIDENCE STAIRCASE -->
                <figure class="article-image">
                    <img src="images/evidence_treatments_timeline.png" alt="A monumental staircase of light ascending from darkness ‚Äî each step represents an increasingly powerful menstrual migraine treatment">
                    <figcaption>The Evidence Staircase ‚Äî From 3-month diary tracking to CGRP monoclonal antibodies: six levels of evidence-based treatment</figcaption>
                </figure>

                <div class="separator">* * *</div>

                <!-- THE KEY QUESTION -->
                <section class="article-section">
                    <h2>The Key Question</h2>
                    <p>Menstrual migraine is not a vague complaint. It is a distinct neurobiological event ‚Äî measurable in hormone assays, visible in CGRP concentrations, and increasingly treatable with therapies designed around its specific mechanisms. A 2024 meta-analysis pooling data from more than 9,100 participants across 16 randomized controlled trials of CGRP monoclonal antibodies confirmed that this class of drugs offers significant, reproducible migraine reduction with a favorable safety profile.<sup>[28]</sup></p>
                    <p>The most important step isn't any single medication. It is recognizing the pattern. Three months of tracking can separate menstrual migraine from its look-alikes, unlock treatments that non-menstrual strategies miss, and give you a conversation with your doctor rooted in data rather than frustration.</p>

                    <div class="quote-box">
                        <p>Your cycle is not the enemy. The information it carries is one of the most precise diagnostic tools you possess. Use it.</p>
                    </div>
                </section>

                <!-- KEY TAKEAWAYS -->
                <div class="key-takeaways">
                    <h3>Key Takeaways</h3>
                    <ul>
                        <li>Menstrual migraine strikes in a precise 5-day window (day ‚àí2 to day +3) and is harder, longer, and more treatment-resistant than non-menstrual attacks</li>
                        <li>The trigger is the speed of estrogen decline ‚Äî migraineurs show 46% steeper drops (SWAN, n = 3,302)</li>
                        <li>Three cascades fire simultaneously: serotonin crash, opioid receptor shutdown, prostaglandin surge ‚Üí CGRP activation</li>
                        <li>Frovatriptan 2.5 mg BID reduces menstrual migraine from 67% to 41% (n = 546, p &lt; 0.0001)</li>
                        <li>CGRP antibodies cut menstrual migraine days from 5 to 2 per cycle with 50% responder rates (STRIVE, n = 955, NEJM)</li>
                        <li>3 months of dual diary tracking (migraine + menstrual days) is the diagnostic foundation ‚Äî start there</li>
                    </ul>
                </div>

                <!-- WHEN TO SEE A DOCTOR -->
                <div class="when-to-see-doctor">
                    <h3>When to See a Doctor</h3>
                    <ul>
                        <li>Your migraines cluster around your period and standard treatments don't work</li>
                        <li>You experience migraine with aura and are considering hormonal contraception</li>
                        <li>Attacks last longer than 72 hours or change in character</li>
                        <li>You are entering perimenopause and migraines are worsening</li>
                        <li>You want to discuss CGRP-targeting therapies or frovatriptan mini-prevention</li>
                    </ul>
                    <p>This article is a starting point for conversation with your doctor, not a replacement for medical care.</p>
                </div>

                <!-- REFERENCES -->
                <div class="references">
                    <h3>References</h3>
                    <ol>
                        <li>Stewart WF, Lipton RB, Chee E, et al. Menstrual cycle and headache in a population sample of migraineurs. <em>Neurology</em>. 2000;55(10):1517‚Äì1523.</li>
                        <li>Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition (ICHD-3). <em>Cephalalgia</em>. 2018;38(1):1‚Äì211.</li>
                        <li>Granella F, Sances G, Allais G, et al. Characteristics of menstrual and nonmenstrual attacks in women with menstrually related migraine referred to headache centres. <em>Cephalalgia</em>. 2004;24(8):707‚Äì716.</li>
                        <li>Association of Migraine Disorders. Clinical recommendations for managing menstrual migraine. Updated January 2025.</li>
                        <li>Somerville BW. Estrogen-withdrawal migraine. I. Duration of exposure required and attempted prophylaxis by premenstrual estrogen administration. <em>Neurology</em>. 1975;25(3):239‚Äì244.</li>
                        <li>Raffaelli B, Do TP, Chaudhry BA, et al. Menstrual migraine is caused by estrogen withdrawal: revisiting the evidence. <em>J Headache Pain</em>. 2023;24(1):131. <a href="https://doi.org/10.1186/s10194-023-01667-1" target="_blank">doi:10.1186/s10194-023-01667-1</a></li>
                        <li>Pavloviƒá JM, Allshouse AA, Engel NL, et al. Sex hormones in women with and without migraine: evidence of migraine-specific hormone profiles. <em>Neurology</em>. 2016;87(1):49‚Äì56. <a href="https://doi.org/10.1212/WNL.0000000000002798" target="_blank">doi:10.1212/WNL.0000000000002798</a></li>
                        <li>MacGregor EA, Frith A, Ellis J, Aspinall L, Hackshaw A. Incidence of migraine relative to menstrual cycle phases of rising and falling estrogen. <em>Neurology</em>. 2006;67(12):2154‚Äì2158.</li>
                        <li>Moy G, Gupta V. Menstrual-related headache. <em>StatPearls</em>. Updated 2022 Oct 4.</li>
                        <li>Allais G, Chiarle G, Sinigaglia S, et al. Menstrual migraine: a review of current and developing pharmacotherapies for women. <em>Expert Opin Pharmacother</em>. 2018;19(2):123‚Äì136.</li>
                        <li>Zubieta JK, Smith YR, Bueller JA, et al. Regional mu opioid receptor regulation of sensory and affective dimensions of pain. <em>Science</em>. 2001;293(5528):311‚Äì315.</li>
                        <li>Kim S, Park JW. Sex differences in migraine: bridging the gap with preclinical models. <em>Adv Physiol Educ</em>. 2025 (ahead of print).</li>
                        <li>MacGregor A. Hormones and migraine [podcast transcript]. <em>National Migraine Centre, Heads Up Series</em>. Season 2, Episode 1. 2023.</li>
                        <li>Sances G, Granella F, Nappi RE, et al. Course of migraine during pregnancy and postpartum: a prospective study. <em>Cephalalgia</em>. 2003;23(3):197‚Äì205.</li>
                        <li>Wang SJ, Fuh JL, Lu SR, et al. Migraine prevalence during menopausal transition. <em>Headache</em>. 2003;43(5):470‚Äì478.</li>
                        <li>Martin VT, Pavlovic J, Fanning KM, et al. Perimenopause and menopause are associated with high frequency headache in women with migraine: results of the American Migraine Prevalence and Prevention Study. <em>Headache</em>. 2016;56(2):292‚Äì305. <a href="https://doi.org/10.1111/head.12763" target="_blank">doi:10.1111/head.12763</a></li>
                        <li>Neri I, Granella F, Nappi R, et al. Characteristics of headache at menopause: a clinico-epidemiologic study. <em>Maturitas</em>. 1993;17(1):31‚Äì37.</li>
                        <li>Sances G, Martignoni E, Fioroni L, et al. Naproxen sodium in menstrual migraine prophylaxis: a double-blind, placebo-controlled study. <em>Headache</em>. 1990;30(11):705‚Äì709.</li>
                        <li>Facchinetti F, Sances G, Borella P, et al. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. <em>Headache</em>. 1991;31(5):298‚Äì301.</li>
                        <li>Ziaei S, Kazemnejad A, Sedighi A. The effect of vitamin E on the treatment of menstrual migraine. <em>Med Sci Monit</em>. 2009;15(1):CR16‚ÄìCR19.</li>
                        <li>Silberstein SD, Elkind AH, Schreiber C, Keywood C. A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine. <em>Neurology</em>. 2004;63(2):261‚Äì269. <a href="https://doi.org/10.1212/01.WNL.0000134620.30129.D6" target="_blank">doi:10.1212/01.WNL.0000134620.30129.D6</a></li>
                        <li>Brandes JL, Poole A, Kallela M, et al. Short-term frovatriptan for the prevention of difficult-to-treat menstrual migraine attacks. <em>Cephalalgia</em>. 2009;29(11):1133‚Äì1148. <a href="https://doi.org/10.1111/j.1468-2982.2009.01840.x" target="_blank">doi:10.1111/j.1468-2982.2009.01840.x</a></li>
                        <li>Hu Y, Guan X, Fan L, et al. Triptans in prevention of menstrual migraine: a systematic review with meta-analysis. <em>J Headache Pain</em>. 2013;14(1):7. <a href="https://doi.org/10.1186/1129-2377-14-7" target="_blank">doi:10.1186/1129-2377-14-7</a></li>
                        <li>MacGregor EA. Migraine, menopause and hormone replacement therapy. <em>Post Reprod Health</em>. 2018;24(1):11‚Äì18.</li>
                        <li>Goadsby PJ, Reuter U, Hallstr√∂m Y, et al. A controlled trial of erenumab for episodic migraine. <em>N Engl J Med</em>. 2017;377(22):2123‚Äì2132. <a href="https://doi.org/10.1056/NEJMoa1705848" target="_blank">doi:10.1056/NEJMoa1705848</a></li>
                        <li>Wu Q, Liu X, Ye M, et al. Acute and preventive treatment of menstrual migraine: a meta-analysis. <em>J Headache Pain</em>. 2024;25(1):140. <a href="https://doi.org/10.1186/s10194-024-01848-6" target="_blank">doi:10.1186/s10194-024-01848-6</a></li>
                        <li>Allais G, Chiarle G, Sinigaglia S, et al. Effectiveness and safety of CGRP-mAbs in menstrual-related migraine: a real-world experience. <em>Pain Ther</em>. 2021;10(2):1435‚Äì1450.</li>
                        <li>Rafique N, Al-Asoom LI, Latif R, et al. Efficacy and safety of CGRP monoclonal antibodies for migraine prevention in episodic migraine: a network meta-analysis. <em>Eur J Clin Pharmacol</em>. 2025 (ahead of print). <a href="https://doi.org/10.1007/s00228-025-03934-3" target="_blank">doi:10.1007/s00228-025-03934-3</a></li>
                    </ol>
                </div>

                <div class="article-footer">

                    <!-- AUTHOR CARD -->
                    <div class="author-card">
                        <div class="author-avatar">
                            <img src="images/rustam.jpeg" alt="Rustam Iuldashov">
                        </div>
                        <div class="author-info">
                            <h3>Rustam Iuldashov</h3>
                            <p><strong>Creator &amp; Developer</strong> ‚Äî 30 years living with migraine. Solo developer from Ukraine who built Migraine Companion during wartime. This article reflects both personal experience and current neuroscience findings.</p>
                            <p style="margin-top:8px;font-size:0.8rem;color:var(--text-dark);"><em>Disclosure: The author is the creator of Migraine Companion. This article was written independently and is not sponsored by any pharmaceutical, supplement, or medical device company.</em></p>
                        </div>
                    </div>

                    <!-- EDITORIAL STANDARDS -->
                    <div class="editorial-standards">
                        <h3>How We Create Content</h3>
                        <ul>
                            <li><strong>Peer-reviewed sources only.</strong> We cite research from the <em>New England Journal of Medicine</em>, <em>Neurology</em>, <em>Cephalalgia</em>, <em>The Journal of Headache and Pain</em>, and other authoritative journals.</li>
                            <li><strong>Large-sample evidence prioritized.</strong> Key claims reference RCTs with n = 410‚Äì9,123 and landmark cohort studies (SWAN n = 3,302; AMPP n = 3,664).</li>
                            <li><strong>Source transparency.</strong> All 28 references are numbered and verifiable. DOI links provided where available.</li>
                            <li><strong>Regular updates.</strong> We review articles when significant new research emerges.</li>
                            <li><strong>No conflicts of interest.</strong> We receive no funding from pharmaceutical companies, triptan manufacturers, or CGRP antibody producers.</li>
                        </ul>
                    </div>

                    <!-- CTA BOX -->
                    <div class="cta-box">
                        <h3>Track Your Menstrual Migraine Pattern with Mi</h3>
                        <p>Mi helps you build the dual diary neurologists recommend ‚Äî migraine days alongside menstrual days ‚Äî so patterns emerge that single entries never reveal.</p>
                        <a href="https://apps.apple.com/app/migraine-companion/id6757784441" class="download-btn" target="_blank">
                            <svg width="24" height="24" viewBox="0 0 24 24" fill="currentColor"><path d="M18.71 19.5c-.83 1.24-1.71 2.45-3.05 2.47-1.34.03-1.77-.79-3.29-.79-1.53 0-2 .77-3.27.82-1.31.05-2.3-1.32-3.14-2.53C4.25 17 2.94 12.45 4.7 9.39c.87-1.52 2.43-2.48 4.12-2.51 1.28-.02 2.5.87 3.29.87.78 0 2.26-1.07 3.81-.91.65.03 2.47.26 3.64 1.98-.09.06-2.17 1.28-2.15 3.81.03 3.02 2.65 4.03 2.68 4.04-.03.07-.42 1.44-1.38 2.83M13 3.5c.73-.83 1.94-1.46 2.94-1.5.13 1.17-.34 2.35-1.04 3.19-.69.85-1.83 1.51-2.95 1.42-.15-1.15.41-2.35 1.05-3.11z"/></svg>
                            Download on App Store
                        </a>
                    </div>

                    <!-- REVIEW DATES -->
                    <div class="review-dates">
                        <p><em>Last reviewed: February 2026</em></p>
                        <p><em>Next scheduled review: August 2026</em></p>
                    </div>

                </div>

            </div>
        </article>
    </main>

    <footer>
        <div class="container">
            <p class="copyright">¬© 2026 Migraine Companion. Made with üíú in Ukraine.</p>
        </div>
    </footer>
</body>
</html>
